Loading…
GLP-1 Agonist·Endocrinology - Insulins & Injectables
Type 2 Diabetes, reduction of major cardiovascular events
No source link confirmed for this record yet. Its own source notes are under Additional.
Max Dose
1.5 mg/week
Half-life
5 Days
Device
AUTO-INJECTOR
Caution: Pancreatitis
RISK
Avoid / Cautions
Personal/family history of Medullary Thyroid Carcinoma or MEN 2. History of pancreatitis. Pregnancy Category D.
Overview
Once-weekly GLP-1 receptor agonist. Highly prized for its incredibly simple, hidden-needle auto-injector device. Excellent cardiovascular benefits.
Clinical Focus
Provides identical benefits to Ozempic, but often preferred by patients with severe needle phobia.
Bottom Line
Dulaglutide is a once-weekly GLP-1 agonist for type 2 diabetes with cardiovascular benefit, but causes GI side effects and is contraindicated in personal/family history of medullary thyroid carcinoma.
Brand Names
Trulicity
Parenteral
Single-use, pre-filled auto-injector pens (1.5 mg/0.5 mL). The needle is hidden and automatically retracts.
Prescribing & PBS
Authority Required (PBS).
Primary
Type 2 Diabetes, reduction of major cardiovascular events.
Clinical Place
Direct competitor to Semaglutide. Highly effective for T2DM with established cardiovascular disease.
No calculator, monitoring schedule or factsheet is linked to this medicine page yet.